Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 3628: Combined mek and jak inhibition in vitro is an effective strategy in overcoming jak inhibitor resistance in primary myelofibrosis (PMF)

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSamuel ReynoldsSMS. MatonoMKMalathi Kandarpa

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Reynolds et al. (2024) studied this question.

synapsesocial.com/papers/68e72e34b6db6435876a7ce4https://doi.org/10.1158/1538-7445.am2024-3628
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth2025
  2. 2Abstract B040: Understanding and Overcoming RAS-pathway Mediated Therapeutic Resistance and Disease Progression in Myeloproliferative Neoplasms2026
  3. 3Abstract 665: MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as single agent and combined with ruxolitinib2024
  4. 4Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025
  5. 5Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor2025